APS recommends opioids for chronic pain

16 February 2009

A panel of experts from the American Pain Society and the American Academy of Pain Medicine has published clinical practice guidelines to  assist clinicians in prescribing potent opioid pain medications for  patients with chronic non-cancer pain in The Journal of Pain.

APS, AAPM and the Oregon Evidence-based Practice Center at Oregon Health  and Science University collaborated for two years reviewing more than  8,000 published abstracts and non-published studies to assess clinical  evidence, from which their recommendations are based. The panel made 25  specific suggestions and achieved unanimous consensus on nearly all of  them.

Opioid prescribing has increased significantly due to growing  professional acceptance that the drugs can relieve chronic non-cancer  pain, and the guideline acknowledges there are widespread concerns about  increases in prescription opioid abuse, addiction and diversion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight